<SEC-DOCUMENT>0001209191-19-038105.txt : 20190619
<SEC-HEADER>0001209191-19-038105.hdr.sgml : 20190619
<ACCEPTANCE-DATETIME>20190619181814
ACCESSION NUMBER:		0001209191-19-038105
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20190617
FILED AS OF DATE:		20190619
DATE AS OF CHANGE:		20190619

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			BioLexis Pte Ltd.
		CENTRAL INDEX KEY:			0001716335

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37759
		FILM NUMBER:		19907062

	BUSINESS ADDRESS:	
		STREET 1:		36 ROBINSON ROAD, #13-01 CITY HOUSE
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			068877
		BUSINESS PHONE:		962 6 582 7999

	MAIL ADDRESS:	
		STREET 1:		36 ROBINSON ROAD, #13-01 CITY HOUSE
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			068877

	FORMER NAME:	
		FORMER CONFORMED NAME:	GMS Tenshi Holdings Pte. Ltd
		DATE OF NAME CHANGE:	20170906

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Pillai Arun Kumar
		CENTRAL INDEX KEY:			0001717437

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37759
		FILM NUMBER:		19907063

	MAIL ADDRESS:	
		STREET 1:		#30, "GALAXY," 1ST MAIN
		STREET 2:		J.P. NAGAR 3RD PHASE
		CITY:			BANGALORE
		STATE:			K7
		ZIP:			560078

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Sukhtian Ghiath M.
		CENTRAL INDEX KEY:			0001717441

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37759
		FILM NUMBER:		19907064

	MAIL ADDRESS:	
		STREET 1:		7TH CIRCLE, ZAHRAN ST.
		STREET 2:		ZAHRAN PLAZA BUILDING, 4TH FLOOR
		CITY:			AMMAN
		STATE:			M2
		ZIP:			11844

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Outlook Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001649989
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				383982704
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	BUSINESS ADDRESS:	
		STREET 1:		7 CLARKE DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
		BUSINESS PHONE:		6096193990

	MAIL ADDRESS:	
		STREET 1:		7 CLARKE DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Oncobiologics, Inc.
		DATE OF NAME CHANGE:	20150804
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2019-06-17</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001649989</issuerCik>
        <issuerName>Outlook Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>OTLK</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001716335</rptOwnerCik>
            <rptOwnerName>BioLexis Pte Ltd.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>36 ROBINSON ROAD</rptOwnerStreet1>
            <rptOwnerStreet2>#13-01 CITY HOUSE</rptOwnerStreet2>
            <rptOwnerCity>SINGAPORE</rptOwnerCity>
            <rptOwnerState>U0</rptOwnerState>
            <rptOwnerZipCode>068877</rptOwnerZipCode>
            <rptOwnerStateDescription>SINGAPORE</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001717437</rptOwnerCik>
            <rptOwnerName>Pillai Arun Kumar</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>#30, 1ST MAIN</rptOwnerStreet1>
            <rptOwnerStreet2>J.P. NAGAR 3RD PHASE</rptOwnerStreet2>
            <rptOwnerCity>BANGALORE</rptOwnerCity>
            <rptOwnerState>K7</rptOwnerState>
            <rptOwnerZipCode>560078</rptOwnerZipCode>
            <rptOwnerStateDescription>INDIA</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001717441</rptOwnerCik>
            <rptOwnerName>Sukhtian Ghiath M.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>7TH CIRCLE, ZAHRAN STREET</rptOwnerStreet1>
            <rptOwnerStreet2>ZAHRAN PLAZA BLDG, 4TH FLOOR</rptOwnerStreet2>
            <rptOwnerCity>AMMAN</rptOwnerCity>
            <rptOwnerState>M2</rptOwnerState>
            <rptOwnerZipCode>11844</rptOwnerZipCode>
            <rptOwnerStateDescription>JORDAN</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2019-06-17</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>M</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>2181818</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>14039494</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                    <footnoteId id="F3"/>
                    <footnoteId id="F4"/>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Warrant (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>2.90</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2019-06-17</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>M</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>3636364</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <value>2019-04-12</value>
            </exerciseDate>
            <expirationDate>
                <value>2020-07-12</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>3636364</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                    <footnoteId id="F3"/>
                    <footnoteId id="F4"/>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Represents the actual number of shares of common stock received upon the exchange of such warrant in full in accordance with its terms.</footnote>
        <footnote id="F2">Such warrant provides for the receipt of .60 of the underlying shares in a cashless exercise in the event the weighted average price is lower than the exercise price per share beginning May 12, 2019.</footnote>
        <footnote id="F3">These securities are held of record by BioLexis. Tenshi Life Sciences Private Limited (&quot;Tenshi&quot;), a private investment vehicle controlled by Arun Kumar Pillai (&quot;Kumar&quot;), and GMS Pharma (Singapore) Pte. Limited (&quot;GMS Pharma&quot;), a private investment company and wholly-owned subsidiary of GMS Holdings, are the 50:50 beneficial owners of BioLexis, in which each of Tenshi and GMS Pharma owns 50% of the outstanding voting shares. Kumar, a natural person, is the holder of a controlling interest in Tenshi. Ghiath M. Sukhtian (&quot;Ghiath Sukhtian&quot;), a natural person, is the holder of a controlling interest in GMS Holdings, which is the holder of a controlling interest in GMS Pharma.</footnote>
        <footnote id="F4">By virtue of the relationships described above in Footnote 2, Kumar and Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by BioLexis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the &quot;Exchange Act&quot;). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. BioLexis has designated four representatives to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ BioLexis Pte. Ltd., By: Faisal G. Sukhtian, Director</signatureName>
        <signatureDate>2019-06-19</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Arun Kumar Pillai</signatureName>
        <signatureDate>2019-06-19</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Ghiath M. Sukhtian</signatureName>
        <signatureDate>2019-06-19</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
